{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:57:01Z","timestamp":1790794621717,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,11,4]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The population was a subset from ALIGN, a multicountry, cross-sectional, self-administered survey study in adult patients (n=7328) with six immune-mediated inflammatory diseases who were routinely receiving systemic therapy. Instruments included Beliefs about Medicines Questionnaire (BMQ) and 4-item Morisky Medication Adherence Scale (MMAS-4\n                      <jats:sup>\u00a9<\/jats:sup>\n                      ), which was used to define adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3390 rheumatological patients were analysed (RA, n=1943; PsA, n=635; AS, n=812). Based on the strongest significant associations, the adherence prediction models included type of treatment, age, race (RA and AS) or disease duration (PsA) and medication beliefs (RA and PsA, BMQ-General\n                      <jats:italic>Harm<\/jats:italic>\n                      score; AS, BMQ-Specific\n                      <jats:italic>Concerns<\/jats:italic>\n                      score). The models had cross-validated areas under the receiver operating characteristic curve of 0.637 (RA), 0.641 (PsA) and 0.724 (AS). Predicted probabilities of full adherence (MMAS-4\n                      <jats:sup>\u00a9<\/jats:sup>\n                      =4) ranged from 5% to 96%. Adherence was highest for tumour necrosis factor inhibitors versus other treatments, older patients and those with low treatment harm beliefs or concerns. Adherence was higher in white patients with RA and AS and in patients with PsA with duration of disease &lt;9 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For the first time, simple medication adherence prediction models for patients with RA, PsA and AS are available, which may help identify patients at high risk of non-adherence to systemic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12612000977875.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2017-000585","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T02:49:25Z","timestamp":1547261365000},"page":"e000585","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study"],"prefix":"10.1136","volume":"5","author":[{"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, Medical University of Vienna and Hietzing Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Patrick","family":"McNeil","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Hojnik","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Rheumatology, AbbVie s.r.o., Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Nurwakagari","sequence":"additional","affiliation":[{"name":"Medical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Weinman","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"2025090313142717000_5.1.e000585.1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181e8bcb0"},{"key":"2025090313142717000_5.1.e000585.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu358"},{"key":"2025090313142717000_5.1.e000585.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.37917"},{"key":"2025090313142717000_5.1.e000585.4","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-014-0460-5","article-title":"Economics of non-adherence to biologic therapies in rheumatoid arthritis","volume":"16","author":"De Vera","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313142717000_5.1.e000585.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80063-X"},{"key":"2025090313142717000_5.1.e000585.6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0256-7"},{"key":"2025090313142717000_5.1.e000585.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080633","article-title":"Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework","volume":"8","author":"Horne","year":"2013","journal-title":"PLoS One"},{"key":"2025090313142717000_5.1.e000585.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150414"},{"key":"2025090313142717000_5.1.e000585.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933"},{"key":"2025090313142717000_5.1.e000585.10","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.962081"},{"key":"2025090313142717000_5.1.e000585.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113308"},{"key":"2025090313142717000_5.1.e000585.12","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313142717000_5.1.e000585.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20258"},{"key":"2025090313142717000_5.1.e000585.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090313142717000_5.1.e000585.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"2025090313142717000_5.1.e000585.16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12325-016-0441-3","article-title":"Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study","volume":"34","author":"Michetti","year":"2017","journal-title":"Adv Ther"},{"key":"2025090313142717000_5.1.e000585.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2005.10.020"},{"key":"2025090313142717000_5.1.e000585.18","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2015.1070851"},{"key":"2025090313142717000_5.1.e000585.19","doi-asserted-by":"publisher","DOI":"10.1080\/08870449908407311"},{"key":"2025090313142717000_5.1.e000585.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.002"},{"key":"2025090313142717000_5.1.e000585.21","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"2025090313142717000_5.1.e000585.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2025090313142717000_5.1.e000585.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"2025090313142717000_5.1.e000585.24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313142717000_5.1.e000585.25","doi-asserted-by":"publisher","DOI":"10.1370\/afm.238"},{"key":"2025090313142717000_5.1.e000585.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10979-005-6832-7"},{"key":"2025090313142717000_5.1.e000585.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.09.001"},{"key":"2025090313142717000_5.1.e000585.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11517-011-0785-4"},{"key":"2025090313142717000_5.1.e000585.29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","article-title":"Development and validation of a predictive model for nonadherence with once-daily glaucoma medications","volume":"120","author":"Chang","year":"2013","journal-title":"Ophthalmology"},{"key":"2025090313142717000_5.1.e000585.30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/petr.12479","article-title":"Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients","volume":"19","author":"Connelly","year":"2015","journal-title":"Pediatr Transplant"},{"key":"2025090313142717000_5.1.e000585.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147443","article-title":"The scale of self-efficacy expectations of adherence to antiretroviral treatment: a tool for identifying risk for non-adherence to treatment for HIV","volume":"11","author":"Drachler","year":"2016","journal-title":"PLoS One"},{"key":"2025090313142717000_5.1.e000585.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-014-0220-z","article-title":"A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study","volume":"14","author":"Kawakami","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"2025090313142717000_5.1.e000585.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh587"},{"key":"2025090313142717000_5.1.e000585.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.12.001"},{"key":"2025090313142717000_5.1.e000585.35","doi-asserted-by":"publisher","DOI":"10.1080\/13548500410001721909"},{"key":"2025090313142717000_5.1.e000585.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081204"},{"key":"2025090313142717000_5.1.e000585.37","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2147\/PPA.S66849","article-title":"Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis","volume":"8","author":"Zwikker","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2025090313142717000_5.1.e000585.38","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00296-017-3758-6","article-title":"Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study","volume":"37","author":"Mena-Vazquez","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025090313142717000_5.1.e000585.39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313142717000_5.1.e000585.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"2025090313142717000_5.1.e000585.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:14:37Z","timestamp":1756930477000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,11]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/rmdopen-2017-000585"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000585","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}